@article{article_764906, title={Higher serum Endocan levels are involved in the pathophysiology of chronic venous insufficiency}, journal={Ege Tıp Dergisi}, volume={59}, pages={310–315}, year={2020}, DOI={10.19161/etd.834331}, author={Doğduş, Mustafa and Koç, Aydın}, keywords={Endokan, kronik venöz yetmezlik, endotel disfonksiyonu}, abstract={Aim: Chronic venous insufficiency (CVI) is a common but neglected pathology of the cardiovascular system with high diagnosis and treatment costs and negative effects on patients’ quality of life. Endocan is a dermatan sulfate proteoglycan and secreted by activated vascular endothelium. We hypothesized that higher Endocan levels may be associated with the pathophysiology of CVI. Thus, in the current study, we aimed to assess the relationship between serum Endocan levels and CVI.
Materials and Methods: Forty-four patients with CVI and 50 age- and gender- matched subjects were enrolled into the study. The baseline clinical characteristics of the patients were obtained and serum Endocan levels were calculated.
Results: The mean Endocan level and mean triglyceride (TG) level were significantly higher in the CVI (+) group compared to the CVI (-) group (p<0.001 and p=0.001, respectively). In multivariate logistic regression analysis; Endocan (p<0.001, Odds ratio (OR) = 3.48, 95% Confidence interval (C.I.) = 1.54–8.16), and TG (p=0.009, OR = 1.85, 95% C.I. = 1.36–3.55) were found to be independent predictors of CVI. ROC analysis was performed to find out the ideal Endocan cut-off value for predicting CVI. An Endocan value of >2.58 ng/mL has 92.4% sensitivity, 76.6% specificity for the prediction of the CVI (AUC 0.841, (p<0.001)).
Conclusions: In the present study, we evaluated the relationship between serum Endocan levels and CVI. Our findings suggest that increased Endocan levels may be involved in the pathogenesis of CVI.}, number={4}, publisher={Ege Üniversitesi}